本文關(guān)鍵詞：華奧膠囊對(duì)糖尿病合并早期大血管病變的炎性因子及ICAM-1、VCAM-1和MCP-1的影響　出處：《河南中醫(yī)學(xué)院》2015年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 華奧膠囊 糖尿病合并大血管病變 炎性因子 ICAM-1 VCAM-1 MCP-1

【摘要】：目的:通過觀察華奧膠囊對(duì)糖尿病合并早期大血管病變大鼠模型的體重、血脂、血糖、炎性因子及粘附分子的影響,探討其對(duì)糖尿病大血管的保護(hù)作用。方法:以健康雄性SD大鼠為實(shí)驗(yàn)對(duì)象,隨機(jī)分為空白對(duì)照組和造模組,其中造模組給予高糖、高脂飼料喂養(yǎng)后給予STZ腹腔注射造模。將造模成功后大鼠隨機(jī)分為模型組、華奧膠囊低劑量組、華奧膠囊高劑量組和通心絡(luò)膠囊組。治療組大鼠分別予華奧膠囊懸液和通心絡(luò)膠囊懸液灌胃,模型組和空白對(duì)照組予同等量生理鹽水灌胃,灌胃8周后大鼠麻醉分離腹主動(dòng)脈和胸主動(dòng)脈,取腹主動(dòng)脈血和胸主動(dòng)脈組織,檢測體重、血糖、總膽固醇、甘油三酯;通過競爭性放射免疫分析方法測定炎性因子TNF-a、CRP、IL-6水平;采用ELISA(競爭法)方法檢測ICAM-1、VCAM-1、MCP-1的表達(dá),觀察各組大鼠胸主動(dòng)脈病理變化。結(jié)果:①正常組大鼠活動(dòng)自如,狀態(tài)良好;模型組大鼠出現(xiàn)多飲、多尿、多食、體重下降、乏力、倦怠、尾部潰爛愈合差等變現(xiàn);治療組大鼠表現(xiàn)較模型組癥狀輕。②治療前大鼠體重對(duì)比差異無統(tǒng)計(jì)學(xué)意義(P0.05);治療后模型組、華奧低劑量組、華奧高劑量組、通心絡(luò)組體重均與空白對(duì)照組比較差異有統(tǒng)計(jì)學(xué)意義(P0.05);治療后華奧高劑量組與華奧膠囊低劑量組、模型組、通心絡(luò)組比較差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。③各組大鼠造模成功后1周、2周、4周和治療后8周血糖變化與空白對(duì)照組對(duì)比明顯升高,差異有統(tǒng)計(jì)學(xué)意義(p0.05);造模后各時(shí)期及治療后華奧高劑量組、模型組、華奧低劑量、通心絡(luò)組4組血糖水平相互對(duì)比差異均無統(tǒng)計(jì)學(xué)意義(p0.05)。④治療后華奧高劑量組、華奧低劑量組及通心絡(luò)組chol、tg均低于模型組,華奧高劑量組、華奧低劑量組與模型組對(duì)比差異有統(tǒng)計(jì)學(xué)意義(p0.05),華奧高劑量組與華奧低劑量、通心絡(luò)組血脂水平對(duì)比差異均有統(tǒng)計(jì)學(xué)意義(p0.05)。⑤模型組tnf-a、crp及il-6水平均較空白組高,差異有統(tǒng)計(jì)學(xué)意義(p0.05);各治療組與模型組對(duì)比差異有統(tǒng)計(jì)學(xué)意義(p0.05);華奧高劑量組與華奧低劑量組及通心絡(luò)組比較,crp及il-6炎性因子水平均降低,差異有統(tǒng)計(jì)學(xué)意義(p0.05);華奧高劑量組與通心絡(luò)組比較,tn-a炎性因子水平降低,差異有統(tǒng)計(jì)學(xué)意義(p0.05);華奧高劑量組與華奧低劑量組比較,tn-a炎性因子水平雖降低,但差異無統(tǒng)計(jì)學(xué)意義(p0.05)。⑥模型組icam-1、vcam-1和mcp-1較空白組表達(dá)水平高,差異有統(tǒng)計(jì)學(xué)意義(p0.05);各治療組與模型組對(duì)比差異有統(tǒng)計(jì)學(xué)意義(p0.05);華奧高劑量組icam-1、vcam-1和mcp-1的表達(dá)水平均低于華奧低劑量組,差異有統(tǒng)計(jì)學(xué)意義(p0.05);華奧高劑量組mcp-1的表達(dá)水平雖低于通心絡(luò)組,但差異無統(tǒng)計(jì)學(xué)意義(p0.05)。⑦模型組大鼠胸主動(dòng)脈光鏡下病理表現(xiàn)與空白組相比,可見動(dòng)脈壁結(jié)構(gòu)紊亂,內(nèi)膜明顯增厚,內(nèi)皮下見較多聚集的泡沫細(xì)胞、沉積的脂質(zhì),中膜見間質(zhì)膠原纖維增生。各治療組病理表現(xiàn)均較模型組有不同程度減輕,其中華奧膠囊高劑量組和通心絡(luò)組病理改善較明顯。結(jié)論:①華奧膠囊可改善調(diào)節(jié)血脂代謝,降低chol和tg水平;對(duì)血糖調(diào)節(jié)影響不大。②華奧膠囊能夠降低糖尿病合并大血管病變模型大鼠血清TNF-a、CRP及IL-6水平和胸主動(dòng)脈組織ICAM-1、VCAM-1、MCP-1的表達(dá),表明華奧膠囊具有大血管保護(hù)作用,其保護(hù)作用機(jī)制可能與減輕炎癥反應(yīng)有關(guān)。
[Abstract]:Objective: through the observation of Ao Capsule on diabetic rat model of early atherosclerosis in weight, blood lipid, blood glucose, effects of inflammatory cytokines and adhesion molecules, to explore its protective effect on diabetic vascular. Methods: healthy male SD rats were randomly divided into control group and model group as blank. The model group given high sugar, high fat diet after intraperitoneal injection of STZ rats. After the successful model rats were randomly divided into model group, Ao capsule low dose group, haoao capsule high dose group and Tongxinluo capsule group. Treatment group rats respectively to Austria and Tongxinluo capsule suspension capsule suspension gavage, model group and blank control group treated with normal saline. After 8 weeks, rats were anesthetized from the abdominal aorta and thoracic aorta, abdominal aorta blood and aortic tissue, body weight, blood glucose, total cholesterol, triglyceride;. A competitive radioimmunoassay method for the determination of inflammatory factors TNF-a, CRP, IL-6; using ELISA (Competition Law) method for detection of ICAM-1, VCAM-1, MCP-1 expression and pathology of rats thoracic aorta were observed. Results: the normal group rats freely, in good condition; the rats in model group appeared to drink, polyuria, polyphagia, weight loss, fatigue, fatigue, poor tail ulcerated healing treatment group rats were realized; compared with the model group. The symptoms of light weight difference was not statistically significant compared to rats before treatment, after treatment (P0.05); model group, low dose group of sports, sports in high dose group, body weight and the blank control group, there was significant difference between Tongxinluo group (P0.05); after the treatment of Ao high dose group and AO capsule low dose group, model group, Tongxinluo group were statistically significant (P0.05). After 1 weeks, the rats were 2 weeks, 8 weeks after 4 weeks and treatment The change of blood glucose compared with the blank control group was significantly increased, the difference was statistically significant (P0.05); haoao high dose group, each time after treatment and model group after modeling, haoao low dose Tongxinluo group, blood glucose levels of 4 groups comparison showed no significant difference (P0.05). The treatment of high dose group sports after a cup of low dose group and Tongxinluo group CHOL, TG were lower than the model group, haoao high dose group was statistically significant Ao low dose group and model group differences (P0.05), Austria high dose group and low dose difference through sports, Tongxinluo group lipid levels contrast were statistically significant (P0.05). The model group TNF-a, CRP and IL-6 levels were higher than those in control group, the difference was statistically significant (P0.05); the difference was statistically significant in each treatment group compared with the model group (P0.05); haoao high dose group and low dose group and Austria Tongxinluo group, CRP and IL-6 levels of inflammatory factors are Decreased, the difference was statistically significant (P0.05); haoao high dose group and Tongxinluo group, tn-a level of inflammatory factors decreased, the difference was statistically significant (P0.05); comparison of sports in high dose group and low dose group tn-a Austria, inflammatory factor level is lower, but the difference was not statistically significant (P0.05). The model group ICAM-1, VCAM-1 and MCP-1 compared with control group, the high expression level, the difference was statistically significant (P0.05); the difference was statistically significant in each treatment group compared with the model group (P0.05); haoao high dose group ICAM-1, the expression level of VCAM-1 and MCP-1 were lower than that of Ao low dose group, the difference was statistically significant (P0.05); the expression level of sports in high dose group MCP-1 was lower than that of Tongxinluo group, but the difference was not statistically significant (P0.05). Compared with the light of thoracic aorta of rats in the model group and the pathological changes of the blank group, visible arterial wall structure disorder, significant intimal thickening, endothelium with The accumulation of foam cells, the deposition of lipid in the membrane, see interstitial collagen fiber hyperplasia. The treatment groups were compared with the model group, pathological manifestations were alleviated, the Ao capsule high dose group and Tongxinluo group were improved significantly. Conclusion: Austria capsule can improve blood lipid metabolism, reduce chol and TG the level of blood glucose regulation; little effect. The Ao capsule can reduce diabetic macrovascular disease serum TNF-a model rats, ICAM-1, CRP and IL-6 levels and aortic tissue VCAM-1, MCP-1 expression showed that the Ao capsule has large vascular protective effects and its protective mechanism may be associated with inflammatory reaction.

【學(xué)位授予單位】：河南中醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R285.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 周燕;治療糖尿病的中醫(yī)藥研究近況[J];華夏醫(yī)學(xué);2001年04期

2 徐祗順,蔣曉剛,劉海南,傅強(qiáng),許復(fù)郁,劉玉強(qiáng);1型糖尿病大鼠陰莖神經(jīng)型一氧化氮合酶的含量及意義[J];山東醫(yī)科大學(xué)學(xué)報(bào);2001年04期

3 艾智華,孟萍,蔡紅衛(wèi);糖尿病大鼠血、尿、腎臟內(nèi)皮素變化及意義[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2002年08期

4 李全宏,田澤,蔡同一;南瓜提取物對(duì)糖尿病大鼠降糖效果研究[J];營養(yǎng)學(xué)報(bào);2003年01期

5 張斌,高鑫;絲裂原激活蛋白激酶信號(hào)通路與糖尿病并發(fā)癥[J];國外醫(yī)學(xué).內(nèi)分泌學(xué)分冊(cè);2004年05期

6 丁文成;;運(yùn)動(dòng)在糖尿病治療中的作用機(jī)理及實(shí)施原則[J];貴州體育科技;2004年04期

7 梁俊清,丁春華,凌亦凌;糖尿病時(shí)肺內(nèi)氧化與抗氧化系統(tǒng)失衡的研究進(jìn)展[J];河北醫(yī)科大學(xué)學(xué)報(bào);2005年01期

8 陳磊,章新華,聶宏光,金萬寶,李金鳴;早期糖尿病大鼠血中降鈣素基因相關(guān)肽的變化[J];中國醫(yī)科大學(xué)學(xué)報(bào);2005年01期

9 李紅,張哲,翁紅雷,阮昱;糖尿病大鼠腎臟α平滑肌肌動(dòng)蛋白的表達(dá)[J];浙江大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2005年02期

10 李潔;趙明;王燕燕;;糖尿病足的分子生物學(xué)機(jī)制[J];中國臨床康復(fù);2006年12期

相關(guān)會(huì)議論文 前10條

1 王志強(qiáng);陳秀榮;武兵;;(綜述)中藥治療糖尿病及其并發(fā)癥的臨床科研進(jìn)展[A];中國中醫(yī)藥學(xué)會(huì)基層中醫(yī)藥會(huì)議專刊[C];1997年

2 金滿文;韓毅;王妍;陳雷;何婷;沈紀(jì)中;辛欣;李先輝;胡燕;;五甲基槲皮素全面防治2型糖尿病的作用及機(jī)制[A];中國藥理學(xué)會(huì)第十一次全國學(xué)術(shù)會(huì)議�？痆C];2011年

3 周水平;仝小林;;糖尿病陽痿的研究進(jìn)展[A];糖尿病中醫(yī)研究進(jìn)展——全國第六次中醫(yī)糖尿病學(xué)術(shù)會(huì)議論文集[C];2000年

4 黃慧;田浩明;李雄偉;;殼聚糖胰島素微球在糖尿病大鼠中的降糖作用研究[A];中華醫(yī)學(xué)會(huì)第六次全國內(nèi)分泌學(xué)術(shù)會(huì)議論文匯編[C];2001年

5 柳剛;關(guān)廣聚;亓同鋼;傅余芹;李學(xué)剛;孫云;吳濤;文蓉珠;;丹參對(duì)糖尿病大鼠腎臟的保護(hù)作用及其機(jī)制[A];第六次全國中西醫(yī)結(jié)合血瘀證及活血化瘀研究學(xué)術(shù)大會(huì)論文匯編[C];2005年

6 ;血管緊張素-(1-7)對(duì)糖尿病大鼠腎臟影響的研究[A];2005年浙江省內(nèi)科學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2005年

7 仝小林;劉銅華;陳良;;中醫(yī)藥防治糖尿病及其并發(fā)癥研究20年概況及展望[A];第九次全國中醫(yī)糖尿病學(xué)術(shù)大會(huì)論文匯編[C];2006年

8 祁少海;劉坡;舒斌;謝舉臨;徐盈斌;黃勇;毛任翔;劉旭盛;;不同深度糖尿病大鼠燙傷模型的制備[A];第五屆全國燒傷救治專題研討會(huì)燒傷后臟器損害的臨床救治論文匯編[C];2007年

9 韓亭亭;蘇布德格日樂;胡耀敏;劉偉;;2型糖尿病大鼠在急性炎癥狀態(tài)下的反應(yīng)能力研究[A];中華醫(yī)學(xué)會(huì)第十次全國內(nèi)分泌學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2011年

10 陳向芳;劉志民;石勇銓;鄒俊杰;湯瑋;馮曉云;張貝;張?zhí)m予;陽秋良;許娟;岳欣欣;;糖尿病大鼠“內(nèi)源性損害”的作用機(jī)制[A];中華醫(yī)學(xué)會(huì)第十次全國內(nèi)分泌學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2011年

相關(guān)重要報(bào)紙文章 前10條

1 郭賽珊　梁曉春 潘明政;中西醫(yī)結(jié)合治療糖尿病慢性并發(fā)癥可顯著改善癥狀[N];中國中醫(yī)藥報(bào);2007年

2 本報(bào)記者 王樂羊;中西醫(yī)結(jié)合防治糖尿病大有可為[N];中國中醫(yī)藥報(bào);2002年

3 北京協(xié)和醫(yī)院 梁曉春;對(duì)中醫(yī)治糖尿病并發(fā)癥研究的思考[N];中國中醫(yī)藥報(bào);2011年

4 劉燕玲;肥胖是糖尿病的源頭[N];健康報(bào);2006年

5 汪敏;糖尿病皮膚易損元兇找到[N];衛(wèi)生與生活報(bào);2003年

6 仝小林;糖尿病慢性并發(fā)癥論治[N];中國中醫(yī)藥報(bào);2003年

7 林蘭;中西醫(yī)結(jié)合治療糖尿病的前景[N];中國中醫(yī)藥報(bào);2007年

8 北京協(xié)和醫(yī)院中醫(yī)科主任 梁曉春;糖尿病周圍神經(jīng)病變的中西醫(yī)治療進(jìn)展[N];中國醫(yī)藥報(bào);2009年

9 本報(bào)記者 劉艷芳;糖尿病干預(yù)不能忽視抗氧化[N];中國食品報(bào);2012年

10 譚小月;糖尿病與腎病關(guān)系研究的新進(jìn)展[N];中國中醫(yī)藥報(bào);2004年

相關(guān)碩士學(xué)位論文 前10條

1 高峰;骨髓間充質(zhì)干細(xì)胞不同移植方法治療糖尿病的實(shí)驗(yàn)研究[D];暨南大學(xué);2009年

2 吳迪;電針治療糖尿病周圍神經(jīng)病的臨床觀察及其作用機(jī)制的實(shí)驗(yàn)研究[D];黑龍江中醫(yī)藥大學(xué);2009年

3 張紅霞;2型糖尿病患者血清tHcy水平與認(rèn)知功能障礙的關(guān)系[D];山東大學(xué);2009年

4 侯亞利;2型糖尿病患者心臟結(jié)構(gòu)和功能的變化[D];蘭州大學(xué);2010年

5 袁海潑;通絡(luò)糖泰方對(duì)糖尿病周圍神經(jīng)病變大鼠血清IL-6水平表達(dá)影響的研究[D];成都中醫(yī)藥大學(xué);2009年

6 張麗;2型糖尿病患者的肺功能變化及其相關(guān)因素分析[D];新疆醫(yī)科大學(xué);2010年

7 程晶;半導(dǎo)體激光聯(lián)合高壓電位對(duì)糖尿病大鼠血管病變作用機(jī)理研究[D];黑龍江中醫(yī)藥大學(xué);2010年

8 邱作成;健脾腎化瘀濁法治療糖尿病多發(fā)性周圍神經(jīng)病變的研究[D];新疆醫(yī)科大學(xué);2004年

9 馮智敏;糖尿病對(duì)大鼠正畸牙齒移動(dòng)的影響[D];河北醫(yī)科大學(xué);2006年

10 鄭淑君;胰島素樣生長因子-1與1型糖尿病大鼠骨骼肌病變的關(guān)系[D];山西醫(yī)科大學(xué);2006年

，

本文編號(hào)：1430938